ABVC BioPharma closes $3.39M convertible note sale to fund units, settle Lind claim
What's the deal? ABVC BioPharmaDealroom has a profile for this one. Try Dealroom → (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes, generating about $3.39 million in gross proceeds before fees. The Silicon Valley biopharma sold the notes to institutional and accredited investors under a securities purchase agreement.
The terms: The 17.5% OID notes carry an aggregate principal of $4,106,060 and mature June 30, 2027. After the eight-month anniversary of issuance, holders can convert at 85% of the average of the three VWAPs for the three trading days before conversion, subject to a floor price.
What's the money for? ABVC said it will use net proceeds for general working capital, funding its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a release and settlement agreement. WallachBeth CapitalDealroom has a profile for this one. Try Dealroom → acted as placement agent.
What's the endgame? The company runs dedicated platforms across its development areas: AiBtl BioPharmaDealroom has a profile for this one. Try Dealroom → for central nervous system drugs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic devices, and BioKey (Cayman)Dealroom has a profile for this one. Try Dealroom → for contract development and manufacturing. It aims to advance programs through licensing, milestone payments, royalties, and equity value.
What could go wrong? The notes are senior and convertible, so the headline figure understates the cost to existing shareholders — the 17.5% discount, repayment terms, and potential dilution all weigh in. ABVC has reported ongoing losses and operating cash outflows, and repaying earlier Lind notes did not resolve its underlying cash pressure.
The signal: For a company leaning on repeated capital raises, this round reads more as a liquidity fix than a growth bet. The convertible structure buys time while adding to the debt and dilution that existing holders must absorb.
Read more: finanznachrichten.de
Image credit: Generated with Gemini
